XNASSTIM
Market cap48mUSD
Jan 08, Last price
1.50USD
1D
-2.60%
1Q
74.42%
IPO
-94.36%
Name
Neuronetics Inc
Chart & Performance
P/E
—
P/S
0.67
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
26.21%
Rev. gr., 5y
6.22%
Revenues
71m
+9.42%
Net income
-30m
L-23.00%
CFO
-32m
L+4.23%
Earnings
May 05, 2025
Profile
Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrists. Neuronetics, Inc. was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.
IPO date
Jun 28, 2018
Employees
209
Domiciled in
US
Incorporated in
US
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||
Revenues | 71,348 9.42% | 65,206 17.89% | ||||||
Cost of revenue | 101,902 | 100,317 | ||||||
Unusual Expense (Income) | ||||||||
NOPBT | (30,554) | (35,111) | ||||||
NOPBT Margin | ||||||||
Operating Taxes | (24) | 2,048 | ||||||
Tax Rate | ||||||||
NOPAT | (30,530) | (37,159) | ||||||
Net income | (30,189) -23.00% | (39,207) 10.13% | ||||||
Dividends | ||||||||
Dividend yield | ||||||||
Proceeds from repurchase of equity | 1,000 | 298 | ||||||
BB yield | 0.00% | -0.16% | ||||||
| Debt | ||||||||
Debt current | 1,690 | 13,949 | ||||||
Long-term debt | 64,820 | 29,587 | ||||||
Deferred revenue | 200 | 829 | ||||||
Other long-term liabilities | (22,829) | |||||||
Net debt | 5,267 | (29,564) | ||||||
| Cash flow | ||||||||
Cash from operating activities | (32,038) | (30,739) | ||||||
CAPEX | (2,369) | (3,269) | ||||||
Cash from investing activities | (1,322) | 6,731 | ||||||
Cash from financing activities | 22,697 | 207 | ||||||
FCF | (40,257) | (39,058) | ||||||
| Balance | ||||||||
Cash | 60,582 | 71,878 | ||||||
Long term investments | 661 | 1,222 | ||||||
Excess cash | 57,676 | 69,840 | ||||||
Stockholders' equity | (375,790) | (345,619) | ||||||
Invested Capital | 473,499 | 419,765 | ||||||
ROIC | ||||||||
ROCE | ||||||||
| EV | ||||||||
Common stock shares outstanding | 28,658 | 26,900 | ||||||
Price | 2.90 -57.79% | 6.87 54.04% | ||||||
Market cap | 83,108 -55.03% | 184,803 62.63% | ||||||
EV | 88,375 | 155,239 | ||||||
EBITDA | (28,548) | (33,463) | ||||||
EV/EBITDA | ||||||||
Interest | 5,424 | 4,251 | ||||||
Interest/NOPBT | ||||||||